{
  "study_metadata": {
    "study_id": null,
    "design": "RCT"
  },
  "exposure": {
    "label": "resveratrol",
    "comparator": "oral hypoglycemic agents"
  },
  "outcomes": [
    {
      "name": "HbA1c",
      "timepoint_weeks": 12,
      "arm_name": "intervention",
      "n": 28,
      "baseline_mean": 9.99,
      "baseline_sd": 1.5,
      "followup_mean": 9.65,
      "followup_sd": 1.54,
      "units": "%"
    }
  ],
  "comment_detailed": "The study is a prospective, open‑label, randomized controlled trial evaluating oral resveratrol (250 mg / day) over 12 weeks in type 2 diabetes patients. HbA1c values were reported for the intervention group only, showing a mean reduction from 9.99 % (SD 1.50) to 9.65 % (SD 1.54). The control group data were not provided in the abstract or tables. Study ID (e.g., DOI) was not extracted.",
  "missing_fields": [
    "study_metadata.study_id"
  ],
  "evidence": [
    "\"resveratrol (250 mg/d) along with their oral hypoglycemic agents for a period of 3 months.\"",
    "\"improves the mean hemoglobin A1c (means ± SD, 9.99 ± 1.50 vs 9.65 ± 1.54; P< .05)\"",
    "\"Table 2 shows baseline 9.99 ± 1.50 and follow‑up 9.65 ± 1.54 for the intervention group.\""
  ],
  "comment": "RCT, 12‑week resveratrol, HbA1c reduction reported; study ID missing.",
  "confidence": 0.75
}